Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an ancient herb ease Chemo's worst side effects?

NCT ID NCT03314805

Symptom relief Sponsor: PhytoHealth Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether PG2, a compound from the astragalus root, can reduce fatigue and low white blood cell counts caused by chemotherapy in women with stage II or III breast cancer. Participants receive either PG2 or a placebo alongside their standard chemotherapy. The goal is to see if PG2 helps patients tolerate treatment better and stick with their full course of chemo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PG2 (astragalus polysaccharides)
What this could lead to
If it works, PG2 could offer a natural way to ease chemotherapy side effects like fatigue and low white blood cell counts, helping patients complete their treatment.
What could go wrong
This is a small Phase 2 trial, so results may not apply broadly. PG2 may not reduce side effects better than placebo, and its safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

67 people

The number who actually took part.

Started

Mar 2018

Finished

Aug 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women who are able to provide informed consent * Age 20 years and older * Diagnosis of stage II to III breast cancer * Patients who had undergone surgery for breast cancer treatment. * Planning to receive anthracycline -based adjuvant chemotherapy * Have adequate bone marrow, liver, and renal function * ECOG ≦1 * Willing and able to complete quality of life questionnaires. Exclusion Criteria: * Pregnancy or lactating women. * Baseline BFI score \>3. * History of chronic fatigue syndrome, uncontrolled active infection, active cardiac disease, poor controlled hypertension or diabetes mellitus, any serious medical condition, psychiatric illness, and regular steroid therapy as determined by investigators. * History of previous breast cancer or other malignancy within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer. * Known severe allergy to Astragalus membranaceus or its mayor extracts (polysaccharides).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired agranulocytosis breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer-related fatigue Neutropenia, malignant

Contacts and locations

Locations

  • Chang Gung Memorial Hospital, Kaohsiung Branch

    Kaohsiung City, 833, Taiwan

  • Chang Gung Memorial Hospital, Linkou Branch

    Taoyuan City, 333, Taiwan

  • Chang Gung Memorial Hospital, Lovers Lake branch

    Keelung, 204, Taiwan

  • Chang Gung Memorial Hospital, Taipei Branch

    Taipei, 105, Taiwan

  • E-Da Cancer Hospital

    Kaohsiung City, 824, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.